Literature DB >> 10935470

In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice.

C J Bruns1, M T Harbison, H Kuniyasu, I Eue, I J Fidler.   

Abstract

We determined whether the implantation of human pancreatic cancer cells into the pancreas of nude mice can be used to select variants with increasing metastatic potential. COLO 357 line fast-growing cells were injected into the spleen or pancreas of nude mice. Hepatic metastases were harvested, and tumor cells were reinjected into the spleen or pancreas. This cycle was repeated several times to yield cell lines L3.6sl (spleen to liver) and L3.6pl (pancreas to liver). The variant cells produced significantly higher incidence and number of lymph node and liver metastases than the parental cells. Their increased metastatic potential was associated with increased expression (mRNA and protein) of the proangiogenic molecules basic fibroblast growth factor, vascular endothelial growth factor, and interleukin-8. The metastatic cells also exhibited increased motility and invasiveness, which were associated with increased expression of collagenase type IV (MMP-9) and decreased expression of E-cadherin. Collectively, the data show that the orthotopic implantation of human pancreatic cancer cells in nude mice is a relevant model with which to study the biology of pancreatic cancer metastasis and to select variant cell lines with enhanced metastatic potential.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10935470      PMCID: PMC1764837          DOI: 10.1038/sj.neo.7900005

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  89 in total

Review 1.  The implications of angiogenesis for the biology and therapy of cancer metastasis.

Authors:  I J Fidler; L M Ellis
Journal:  Cell       Date:  1994-10-21       Impact factor: 41.582

2.  Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma.

Authors:  C Gamallo; J Palacios; A Suarez; A Pizarro; P Navarro; M Quintanilla; A Cano
Journal:  Am J Pathol       Date:  1993-04       Impact factor: 4.307

3.  E-cadherin expression in colorectal cancer. An immunocytochemical and in situ hybridization study.

Authors:  S Dorudi; J P Sheffield; R Poulsom; J M Northover; I R Hart
Journal:  Am J Pathol       Date:  1993-04       Impact factor: 4.307

4.  Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas.

Authors:  R K Singh; M Gutman; C D Bucana; R Sanchez; N Llansa; I J Fidler
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

5.  Density-dependent induction of 92-kd type IV collagenase activity in cultures of A431 human epidermoid carcinoma cells.

Authors:  B Xie; C D Bucana; I J Fidler
Journal:  Am J Pathol       Date:  1994-05       Impact factor: 4.307

6.  Monoclonal antibodies specific for endothelial cells of mouse blood vessels. Their application in the identification of adult and embryonic endothelium.

Authors:  A Vecchi; C Garlanda; M G Lampugnani; M Resnati; C Matteucci; A Stoppacciaro; H Schnurch; W Risau; L Ruco; A Mantovani
Journal:  Eur J Cell Biol       Date:  1994-04       Impact factor: 4.492

7.  Molecular cloning and characterization of the human E-cadherin cDNA.

Authors:  M J Bussemakers; A van Bokhoven; S G Mees; R Kemler; J A Schalken
Journal:  Mol Biol Rep       Date:  1993-02       Impact factor: 2.316

8.  Differences of E-cadherin expression levels and patterns in primary and metastatic human lung cancer.

Authors:  M Böhm; B Totzeck; W Birchmeier; I Wieland
Journal:  Clin Exp Metastasis       Date:  1994-01       Impact factor: 5.150

Review 9.  Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis.

Authors:  H F Dvorak; L F Brown; M Detmar; A M Dvorak
Journal:  Am J Pathol       Date:  1995-05       Impact factor: 4.307

10.  Characterization of cancer cell dissociation factor in a highly invasive pancreatic cancer cell line.

Authors:  T Kurizaki; H Egami; M Hirota; J Akagi; H Ohmachi; S Yamamoto; M Ogawa
Journal:  Cancer       Date:  1995-03-15       Impact factor: 6.860

View more
  141 in total

1.  Role of the nuclear receptor coactivator AIB1-Delta4 splice variant in the control of gene transcription.

Authors:  Christopher D Chien; Alexander Kirilyuk; Jordan V Li; Wentao Zhang; Tyler Lahusen; Marcel O Schmidt; Annabell S Oh; Anton Wellstein; Anna T Riegel
Journal:  J Biol Chem       Date:  2011-06-02       Impact factor: 5.157

2.  Downstream mediators of the intratumoral interferon response suppress antitumor immunity, induce gemcitabine resistance and associate with poor survival in human pancreatic cancer.

Authors:  Daniel Delitto; Chelsey Perez; Song Han; David H Gonzalo; Kien Pham; Andrea E Knowlton; Christina L Graves; Kevin E Behrns; Lyle L Moldawer; Ryan M Thomas; Chen Liu; Thomas J George; Jose G Trevino; Shannon M Wallet; Steven J Hughes
Journal:  Cancer Immunol Immunother       Date:  2015-09-30       Impact factor: 6.968

3.  Manipulation of Cell-Type Selective Antibody Internalization by a Guide-Effector Bispecific Design.

Authors:  Nam-Kyung Lee; Yang Su; Scott Bidlingmaier; Bin Liu
Journal:  Mol Cancer Ther       Date:  2019-04-08       Impact factor: 6.261

4.  The RON-receptor regulates pancreatic cancer cell migration through phosphorylation-dependent breakdown of the hemidesmosome.

Authors:  Peter T Yu; Michele Babicky; Dawn Jaquish; Randy French; Karly Marayuma; Evangeline Mose; Sherry Niessen; Heather Hoover; David Shields; David Cheresh; Benjamin F Cravatt; Andrew M Lowy
Journal:  Int J Cancer       Date:  2012-03-08       Impact factor: 7.396

5.  Protein kinase Ciota is required for pancreatic cancer cell transformed growth and tumorigenesis.

Authors:  Michele L Scotti; William R Bamlet; Thomas C Smyrk; Alan P Fields; Nicole R Murray
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

6.  The role of tumor cell-derived connective tissue growth factor (CTGF/CCN2) in pancreatic tumor growth.

Authors:  Kevin L Bennewith; Xin Huang; Christine M Ham; Edward E Graves; Janine T Erler; Neeraja Kambham; Jonathan Feazell; George P Yang; Albert Koong; Amato J Giaccia
Journal:  Cancer Res       Date:  2009-02-01       Impact factor: 12.701

7.  Butyrate inhibits pancreatic cancer invasion.

Authors:  Buckminster Farrow; Piotr Rychahou; Kathleen L O'Connor; B Mark Evers
Journal:  J Gastrointest Surg       Date:  2003-11       Impact factor: 3.452

8.  A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells.

Authors:  Jianliang Zhang; Di-Hua He; Maria Zajac-Kaye; Steven N Hochwald
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

9.  Lack of host SPARC enhances vascular function and tumor spread in an orthotopic murine model of pancreatic carcinoma.

Authors:  Shanna A Arnold; Lee B Rivera; Andrew F Miller; Juliet G Carbon; Sean P Dineen; Yang Xie; Diego H Castrillon; E Helene Sage; Pauli Puolakkainen; Amy D Bradshaw; Rolf A Brekken
Journal:  Dis Model Mech       Date:  2009-12-09       Impact factor: 5.758

10.  TrkBT1 induces liver metastasis of pancreatic cancer cells by sequestering Rho GDP dissociation inhibitor and promoting RhoA activation.

Authors:  Zhongkui Li; Zhe Chang; Lucia J Chiao; Ya'an Kang; Qianghua Xia; Cihui Zhu; Jason B Fleming; Douglas B Evans; Paul J Chiao
Journal:  Cancer Res       Date:  2009-09-22       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.